Cargando…

Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine

INTRODUCTION: Serious infections of Pseudomonas aeruginosa (PA) in hospitals and the emergence and increase of multidrug resistance have raised an urgent need for effective vaccines. However, no vaccine has been approved to date. One possible reason for this is the limited immune response due to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuhang, Pu, Ruixue, Zhang, Yi, Zhang, Yiwen, Wei, Yujie, Zeng, Sheng, Gao, Chen, Wang, Ying, Yin, Daijiajia, Zhang, Yueyue, Wan, Jiqing, Zou, Quanming, Gu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321299/
https://www.ncbi.nlm.nih.gov/pubmed/37415986
http://dx.doi.org/10.3389/fimmu.2023.1184863
_version_ 1785068596065468416
author Li, Yuhang
Pu, Ruixue
Zhang, Yi
Zhang, Yiwen
Wei, Yujie
Zeng, Sheng
Gao, Chen
Wang, Ying
Yin, Daijiajia
Zhang, Yueyue
Wan, Jiqing
Zou, Quanming
Gu, Jiang
author_facet Li, Yuhang
Pu, Ruixue
Zhang, Yi
Zhang, Yiwen
Wei, Yujie
Zeng, Sheng
Gao, Chen
Wang, Ying
Yin, Daijiajia
Zhang, Yueyue
Wan, Jiqing
Zou, Quanming
Gu, Jiang
author_sort Li, Yuhang
collection PubMed
description INTRODUCTION: Serious infections of Pseudomonas aeruginosa (PA) in hospitals and the emergence and increase of multidrug resistance have raised an urgent need for effective vaccines. However, no vaccine has been approved to date. One possible reason for this is the limited immune response due to the lack of an efficient delivery system. Self-assembled ferritin nanoparticles are good carriers of heterogeneous antigens, which enhance the activation of immunological responses. METHODS: In this study, two well-studied antigen candidates, PcrV and OprI, were selected and connected to the ferritin nanoparticle by the Spytag/SpyCatcher system to generate the nanovaccine rePO-FN. RESULTS: Compared to recombinant PcrV-OprI formulated with aluminum adjuvants, intramuscular immunization with adjuvant-free rePO-FN induced quick and efficient immunity and conferred protection against PA pneumonia in mice. In addition, intranasal immunization with adjuvant-free rePO-FN enhanced protective mucosal immunity. Moreover, rePO-FN exhibited good biocompatibility and safety. DISCUSSION: Our results suggest that rePO-FN is a promising vaccine candidate, as well as, provide additional evidence for the success of ferritin-based nanovaccines.
format Online
Article
Text
id pubmed-10321299
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103212992023-07-06 Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine Li, Yuhang Pu, Ruixue Zhang, Yi Zhang, Yiwen Wei, Yujie Zeng, Sheng Gao, Chen Wang, Ying Yin, Daijiajia Zhang, Yueyue Wan, Jiqing Zou, Quanming Gu, Jiang Front Immunol Immunology INTRODUCTION: Serious infections of Pseudomonas aeruginosa (PA) in hospitals and the emergence and increase of multidrug resistance have raised an urgent need for effective vaccines. However, no vaccine has been approved to date. One possible reason for this is the limited immune response due to the lack of an efficient delivery system. Self-assembled ferritin nanoparticles are good carriers of heterogeneous antigens, which enhance the activation of immunological responses. METHODS: In this study, two well-studied antigen candidates, PcrV and OprI, were selected and connected to the ferritin nanoparticle by the Spytag/SpyCatcher system to generate the nanovaccine rePO-FN. RESULTS: Compared to recombinant PcrV-OprI formulated with aluminum adjuvants, intramuscular immunization with adjuvant-free rePO-FN induced quick and efficient immunity and conferred protection against PA pneumonia in mice. In addition, intranasal immunization with adjuvant-free rePO-FN enhanced protective mucosal immunity. Moreover, rePO-FN exhibited good biocompatibility and safety. DISCUSSION: Our results suggest that rePO-FN is a promising vaccine candidate, as well as, provide additional evidence for the success of ferritin-based nanovaccines. Frontiers Media S.A. 2023-06-21 /pmc/articles/PMC10321299/ /pubmed/37415986 http://dx.doi.org/10.3389/fimmu.2023.1184863 Text en Copyright © 2023 Li, Pu, Zhang, Zhang, Wei, Zeng, Gao, Wang, Yin, Zhang, Wan, Zou and Gu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Yuhang
Pu, Ruixue
Zhang, Yi
Zhang, Yiwen
Wei, Yujie
Zeng, Sheng
Gao, Chen
Wang, Ying
Yin, Daijiajia
Zhang, Yueyue
Wan, Jiqing
Zou, Quanming
Gu, Jiang
Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
title Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
title_full Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
title_fullStr Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
title_full_unstemmed Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
title_short Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
title_sort self-assembled ferritin nanoparticles displaying pcrv and opri as an adjuvant-free pseudomonas aeruginosa vaccine
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321299/
https://www.ncbi.nlm.nih.gov/pubmed/37415986
http://dx.doi.org/10.3389/fimmu.2023.1184863
work_keys_str_mv AT liyuhang selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT puruixue selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT zhangyi selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT zhangyiwen selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT weiyujie selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT zengsheng selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT gaochen selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT wangying selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT yindaijiajia selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT zhangyueyue selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT wanjiqing selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT zouquanming selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine
AT gujiang selfassembledferritinnanoparticlesdisplayingpcrvandopriasanadjuvantfreepseudomonasaeruginosavaccine